ONCOCROSS

  • ONCOCROSS

    • Mission

    • History

    • Leadership

    • Scientific Advisory Board

  • Technology

    • Platform

    • ONCOCROSS AI Platform

      • RAPTOR AI™

      • ONCO-RAPTOR AI™

      • ONCOfind AI™

    • in vitro / in vivo analysis

  • Collaboration

    • New Indication

    • Optimal Cancer Type Identification

    • CUP Primary Site Identification

  • News/IR

    • Announcement

    • Press

    • Regulatory Disclosure

    • Stock Information

CONTACT US
한
  • ONCOCROSS

    • Mission

    • History

    • Leadership

    • Scientific Advisory Board

  • Technology

    • Platform

    • ONCOCROSS AI Platform

      • RAPTOR AI™

      • ONCO-RAPTOR AI™

      • ONCOfind AI™

    • in vitro / in vivo analysis

  • Collaboration

    • New Indication

    • Optimal Cancer Type Identification

    • CUP Primary Site Identification

  • News/IR

    • Announcement

    • Press

    • Regulatory Disclosure

    • Stock Information

  • 한
  • EN
CONTACT US
  • Main
  • News/IR
  • Press

Press

164 Posts
  • Med Sina

    Oncocross宣布启动在研疗法OC514全球性1期临床试验

    02-28-2022
  • Bloomberg

    Oncocross Begins Clinical Trial for AI-Developed Drug for Sarcopenia

    02-25-2022
  • AP NEWS

    Oncocross Begins Clinical Trial for AI-Developed Drug for Sarcopenia

    02-25-2022
  • Pharmaceutical Daily

    Oncocross Begins Clinical Trial for AI-Developed Drug for Sarcopenia

    02-25-2022
  • 매일경제

    혁신으로 창업하라, K-Company의 비밀'…(주)온코크로스·에이엔폴리

    02-24-2022
  • 매일경제

    온코크로스, AI로 근육질환치료제 후보물질 발굴해 글로벌 임상

    02-23-2022
  • 바이오스펙테이터

    온코크로스, 'AI' 근감소증 후보물질 "호주 1상 시작"

    02-23-2022
  • 메디게이트뉴스

    온코크로스, AI 신약 근감소증 치료제 글로벌 임상시험 개시

    02-23-2022
  • 히트뉴스

    온코크로스, AI로 발굴한 암 전이억제 물질 미 특허 취득

    02-15-2022
  • 파이낸셜뉴스

    10년씩 걸리던 신약개발, AI기술 접목해 확 당긴다

    02-14-2022
  • 월간인물

    환자의 염원에 답하는 ‘의사들의’ AI 신약 개발 기업 ㈜온코크로스, 코스닥 상장으로 새로운 도전

    02-14-2022
  • 팜이데일리

    [온코크로스 대해부]③394개 경쟁사 대비 차별점 갖춰야

    02-11-2022
  • «
  • ‹
  • 6
  • 7
  • 8
  • 9
  • 10
  • ›
  • »

Please enter a prompt

ONCOCROSS
CEO
Yi Rang KIM / Jihoon KANG
Address
#905 7 Beobwon-ro 11-gil, Songpa-gu, Seoul, 05836, Korea
Tel
02-717-9967
Fax
02-867-9968
Email
oncocross@oncocross.com
Terms & Conditions Privacy Policy Cookie Policy
ⓒ ONCOCROSS CO., LTD. All Rights Reserved.